• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统综述更新澳大利亚“统计生命价值”估计。

Systematic Review to Update 'Value of a Statistical Life' Estimates for Australia.

机构信息

Deakin Health Economics, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong, VIC 3220, Australia.

Global Obesity Centre, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong, VIC 3220, Australia.

出版信息

Int J Environ Res Public Health. 2021 Jun 7;18(11):6168. doi: 10.3390/ijerph18116168.

DOI:10.3390/ijerph18116168
PMID:34200344
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8201370/
Abstract

The value of a statistical life (VSL) estimates individuals' willingness to trade wealth for mortality risk reduction. This economic parameter is often a major component of the quantified benefits estimated in the evaluation of government policies related to health and safety. This study reviewed the literature to update the VSL recommended for Australian policy appraisals. A systematic literature review was conducted to capture Australian primary studies and international review papers reporting VSL estimates published from 2007 to January 2019. International estimates were adjusted for income differences and the median VSL estimate was extracted from each review study. VSL estimates were used to calculate the value of a statistical life year. Of the 18 studies that met the inclusion criteria, two studies were primary Australian studies with a weighted mean VSL of A$7.0 million in 2017 values. The median VSL in the review studies was A$7.3 million. For Australian public policy appraisals, we recommend the consideration of a base case VSL for people of all ages and across all risk contexts of A$7.0 million. Sensitivity analyses could use a high value of A$7.3 million and a low value that reflects the value (A$4.3 million) currently recommended by the Australian government.

摘要

统计生命价值 (VSL) 估计个人为降低死亡风险而愿意交换财富的意愿。这个经济参数通常是评估与健康和安全相关的政府政策的量化效益估算中的主要组成部分。本研究回顾了文献,以更新澳大利亚政策评估中推荐的 VSL。进行了系统的文献综述,以获取 2007 年至 2019 年 1 月期间发表的报告 VSL 估计值的澳大利亚主要研究和国际评论文章。对国际估计值进行了收入差异调整,并从每项审查研究中提取了中位数 VSL 估计值。VSL 估计值用于计算统计生命年的价值。在符合纳入标准的 18 项研究中,有两项是澳大利亚的主要研究,加权平均 VSL 在 2017 年的价值为 700 万澳元。综述研究中的中位数 VSL 为 730 万澳元。对于澳大利亚公共政策评估,我们建议考虑所有年龄段和所有风险情况下的基本 VSL 为 700 万澳元。敏感性分析可以使用 730 万澳元的高值和反映澳大利亚政府目前推荐的(430 万澳元)的低值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56c8/8201370/2209c2d130ff/ijerph-18-06168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56c8/8201370/2209c2d130ff/ijerph-18-06168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56c8/8201370/2209c2d130ff/ijerph-18-06168-g001.jpg

相似文献

1
Systematic Review to Update 'Value of a Statistical Life' Estimates for Australia.系统综述更新澳大利亚“统计生命价值”估计。
Int J Environ Res Public Health. 2021 Jun 7;18(11):6168. doi: 10.3390/ijerph18116168.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
4
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
5
Interventions for promoting habitual exercise in people living with and beyond cancer.促进癌症患者及康复者进行习惯性锻炼的干预措施。
Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3.
6
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
What is the economic and social return on investment for telephone cancer information and support services in Australia? An evaluative social return on investment study protocol.澳大利亚电话癌症信息和支持服务的投资经济和社会效益回报是什么?一项评估性社会投资回报研究方案。
BMJ Open. 2024 Jun 25;14(6):e081425. doi: 10.1136/bmjopen-2023-081425.
2
Modelling the cost-effectiveness of brief aftercare interventions following hospital-treated self-harm.模拟医院治疗自残后简短后续护理干预措施的成本效益。
BJPsych Open. 2023 Aug 1;9(5):e139. doi: 10.1192/bjo.2023.525.
3
A state-wide implementation of a whole of hospital sepsis pathway with a mortality based cost-effectiveness analysis from a healthcare sector perspective.

本文引用的文献

1
Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis.在全球效益成本分析中评估死亡率风险降低情况。
J Benefit Cost Anal. 2019;10(Suppl 1):15-50. doi: 10.1017/bca.2018.26. Epub 2019 Jan 15.
2
Policy Brief - What's in a Name? A Search for Alternatives to "VSL".政策简报 - 名称有何含义?寻找“VSL”的替代词
Rev Environ Econ Policy. 2019;13(1):155-161. doi: 10.1093/reep/rey022.
3
SANRA-a scale for the quality assessment of narrative review articles.SANRA——一种用于叙述性综述文章质量评估的量表。
从医疗保健部门的角度出发,在全州范围内实施基于死亡率的成本效益分析的全院脓毒症治疗路径。
PLOS Glob Public Health. 2023 May 19;3(5):e0000687. doi: 10.1371/journal.pgph.0000687. eCollection 2023.
4
The societal value of SARS-CoV-2 booster vaccination in Indonesia.SARS-CoV-2 加强针接种在印度尼西亚的社会价值。
Vaccine. 2023 Mar 10;41(11):1885-1891. doi: 10.1016/j.vaccine.2023.01.068. Epub 2023 Feb 1.
5
Exploring the Health and Economic Burden Among Truck Drivers in Australia: A Health Economic Modelling Study.探索澳大利亚卡车司机的健康和经济负担:一项健康经济建模研究。
J Occup Rehabil. 2023 Jun;33(2):389-398. doi: 10.1007/s10926-022-10081-4. Epub 2022 Nov 10.
6
Cost-effectiveness of media reporting guidelines for the prevention of suicide.媒体报道预防自杀指南的成本效益。
Suicide Life Threat Behav. 2022 Oct;52(5):1048-1057. doi: 10.1111/sltb.12902. Epub 2022 Sep 15.
7
Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.在奥密克戎变异株流行时期,估计扩大在低收入和中低收入国家接种 mRNA COVID-19 疫苗的规模可以避免的死亡人数和每挽救一人的成本:一项建模研究。
BMJ Open. 2022 Sep 13;12(9):e061752. doi: 10.1136/bmjopen-2022-061752.
8
A Dynamic Approach to Economic Priority Setting to Invest in Youth Mental Health and Guide Local Implementation: Economic Protocol for Eight System Dynamics Policy Models.一种动态的经济优先事项设定方法,用于投资青少年心理健康并指导地方实施:八个系统动力学政策模型的经济协议
Front Psychiatry. 2022 Apr 29;13:835201. doi: 10.3389/fpsyt.2022.835201. eCollection 2022.
9
Cost-Benefit and Cost-Utility Analyses to Demonstrate the Potential Value-for-Money of Supermarket Shelf Tags Promoting Healthier Packaged Products in Australia.成本效益和成本效用分析表明,在澳大利亚,超市货架标签促进更健康包装产品具有潜在的性价比。
Nutrients. 2022 May 3;14(9):1919. doi: 10.3390/nu14091919.
10
A cost-benefit analysis framework for preventive health interventions to aid decision-making in Australian governments.用于辅助澳大利亚政府决策的预防性健康干预措施的成本效益分析框架。
Health Res Policy Syst. 2021 Dec 19;19(1):147. doi: 10.1186/s12961-021-00796-w.
Res Integr Peer Rev. 2019 Mar 26;4:5. doi: 10.1186/s41073-019-0064-8. eCollection 2019.
4
Valuing Reductions in Fatal Illness Risks: Implications of Recent Research.重视致命疾病风险的降低:近期研究的启示
Health Econ. 2016 Aug;25(8):1039-52. doi: 10.1002/hec.3214. Epub 2015 Jun 30.
5
Health in All Policies (HiAP) framework for country action.国家行动的“健康融入所有政策”(HiAP)框架。
Health Promot Int. 2014 Jun;29 Suppl 1:i19-28. doi: 10.1093/heapro/dau035.
6
The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.支付意愿以获取质量调整生命年:实证文献综述。
Health Econ. 2015 Oct;24(10):1289-1301. doi: 10.1002/hec.3085. Epub 2014 Jul 28.
7
Value of a statistical life in road safety: a benefit-transfer function with risk-analysis guidance based on developing country data.道路安全中统计生命的价值:基于发展中国家数据的具有风险分析指导的效益转移函数。
Accid Anal Prev. 2014 Oct;71:236-47. doi: 10.1016/j.aap.2014.05.026. Epub 2014 Jun 19.
8
A systematic review of stated preference studies reporting public preferences for healthcare priority setting.系统评价报告公众对医疗保健优先排序的偏好的陈述性偏好研究。
Patient. 2014;7(4):365-86. doi: 10.1007/s40271-014-0063-2.
9
Publication selection and the income elasticity of the value of a statistical life.出版物选择与统计生命价值的收入弹性。
J Health Econ. 2014 Jan;33:67-75. doi: 10.1016/j.jhealeco.2013.10.010. Epub 2013 Nov 6.
10
The value of a statistical life in Sweden: a review of the empirical literature.瑞典的统计生命价值:实证文献综述。
Health Policy. 2012 Dec;108(2-3):302-10. doi: 10.1016/j.healthpol.2012.09.007. Epub 2012 Oct 18.